Clindamycin acts on protein synthesis. It is highly lipid soluble, and penetrates both the eye and dense tissue. It has been used in the treatment of ocular toxoplasmosis and as an alternative treatment of cerebral toxoplasmosis (Luft and Hafner 1990). However, its penetration of CSF is poor. The recommended dose is 600 mg, four times a day. The drug is used together with pyrimethamine because by itself it merely suppresses and does not fully inhibit the spread of the infection in tissues (Piketty et al. 1990). Adverse reaction to clindamycin includes vomiting and diarrhoea. The drug is not teratogenic and can be used during pregnancy, but the effect on prenatal toxoplasmosis is lacking.

Page 265

0 0

Post a comment